Drug intelligence / Profile preview

Anti-CEA CAR-T

Development stage: Unknown
Lead developer: Ruijin Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Anti-CEA CAR-T (Ruijin Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the carcinoembryonic antigen (CEA), a glycoprotein frequently overexpressed in colorectal tumors. Developed by Ruijin Hospital, this cell-based immunotherapy involves genetically modifying a patient's own T cells to express a CAR that recognizes and binds to CEA-expressing cancer cells. It is currently being evaluated in an Early Phase 1 clinical trial (NCT05240950) aimed at preventing postoperative recurrence and metastasis in patients with stage III colorectal cancer or those with colorectal cancer liver metastases. The therapy is administered in a dose-escalating manner to determine safety and optimal dosage for prolonging relapse-free survival.

Other names: Anti-CEA CAR-T cellsCEA-targeted CAR-T cells

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on Anti-CEA CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-CEA CAR-T.

Explore the full profile